Photo from wikipedia
1.14) for women and 1.06 (95% CI: 0.98, 1.14) for men. Results were similar in persons 65 years. IRs for bladder and prostate cancers were higher in both mirabegron and… Click to show full abstract
1.14) for women and 1.06 (95% CI: 0.98, 1.14) for men. Results were similar in persons 65 years. IRs for bladder and prostate cancers were higher in both mirabegron and AM cohorts in the first 6 months after treatment initiation, suggesting protopathic bias. CONCLUSIONS: This large multi-country real-world study, with up to 6 years of follow up, found no evidence of an association between mirabegron use and risk of the studied cancers, compared to AMs, in either men or women.
Keywords:
overactive bladder;
evaluating quality;
education;
patient education;
quality overactive;
pd44 evaluating
Journal Title: Journal of Urology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Urology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!